RNS Number: 1349 C Shield Therapeutics PLC 13 June 2019 Shield Therapeutics plc. Result of 2019 Annual General Meeting. London, UK, 13 th June 2019: Shield Therapeutics plc, a commercial stage, specialty pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces the results of the proxy...
Shield Therapeutics Plc (STX.L) Announced an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA), that TEVA has filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone". No date has been set for the hearing. The company will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office.
RNS Number: 8490 A Shield Therapeutics PLC 03 June 2019 Shield Therapeutics plc. London, UK, 3 June 2019: Shield Therapeutics plc, a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd..
Europe underpins current valuation; await US approval
Read the initiation note on @ShieldTx issued by @finnCap @finnCap initiate with a target price of 200p, although recognition that FDA approval and subsequent licensing would see this rise to at least 250p
Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. Watch more here via @YouTube
RNS Number: 2885 Y Shield Therapeutics PLC 08 May 2019 Shield Therapeutics plc. London, UK, 8 May 2019: Shield Therapeutics plc, a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces the appointment of finnCap Ltd as its joint broker with immediate effect..
London, UK, 2 May 2019. Shield Therapeutics plc, a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces that it will be presenting at the ShareSoc Growth Company Seminar in London on Wednesday 8 May, 2019.. The event will commence at 5.30 pm at the offices of Link Asset...
RNS Number: 7598 X Shield Therapeutics PLC 01 May 2019 Shield Therapeutics plc. London, UK, 1 st May 2019: Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces that it issued and allotted 47,169 Ordinary Shares of 1.5 p each following the...
RNS Number: 2290 X Shield Therapeutics PLC 30 April 2019 Shield Therapeutics plc. London, UK, 30 April 2019. The AGM is scheduled to be held at 10.00 am BST on Thursday 13 June 2019 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London, EC2M 7 SH..
$STX Swiss broad label approval 'a further endorsement' of Shield's Feraccru drug via @proactive_uk @shieldTx #STX #brighterir #AndrewScottTV #CapitalNetwork1
Shield Therapeutics PLC’s (LON:STX) chief executive Carl Sterritt elaborates on the decision by Switzerland’s medical authorities to give approval for its Feraccru iron deficiency drug for all adults with iron deficiency. He says they'll now be able to market the drug to any adult, whether or not they have been diagnosed with anaemia. The news comes ahead of the FDA’s decision on whether to grant marketing approval for Feraccru in the US which is due 27 July 2019.
RNS Number: 3136 X Shield Therapeutics PLC 26 April 2019 Shield Therapeutics plc. London, UK, 26 April 2019, Shield Therapeutics plc, a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru ®, announces that Mark Sampson, Chief Medical Officer, has acquired 22,875 Ordinary...
Shield Therapeutic (STX.L) 88.5p £97.5m The commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announced that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for Feraccru® to now include treatment of all adults with iron deficiency (ID) with or without anaemia. This follows an equivalent broadening of the marketing authorisation approval for Feraccru® in the European Union in 2018 and futher increases the commercial opportunity for Feraccru®, which was initially approved in both the EU and Switzerland just for the treatment of iron deficiency anemia (IDA) in adult patients with inflammatory bowel disease (IBD). “Switzerland represents an attractive market opportunity as it is both well reimbursed and has a much higher level of treatment penetration compared to other markets, particularly for IV iron therapies. “
$STX Shield Therapeutics wins extended approval in Switzerland via @proactive_UK @shieldTx #STX #brighterir #AndrewScottTV #CapitalNetwork1
Shield Therapeutics Plc (STX.L) Announced that the Swiss Agency for Therapeutic Products (Swissmedic) has approved a major extension of the approved indication for FeraccruR to now include treatment of all adults with iron deficiency (ID) with or without anaemia.
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    116.43M

Featured Media

Company Profile

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.

Classification

Market Indices-

Locations

HQ
Northern Design Centre
Baltic Business Quarter
Gatehead Quays
NE8 3DF
Watchlist